TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00168558

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Measles vaccine
Description: The children will be randomised to the following three arms:~Arm 1 - Very early two-dose: V (EZ) 4½ mo of age + V (EZ) 9 mo of age.~Arm 2 - 9 months one- or two-dose: V (SW) 9 mo of age + V (SW)/or nothing 18 mo of age.~Arm 3 - 9 months one- or two-dose: V (EZ) 9 mo of age + V (EZ)/or nothing 18 mo of age.~V = measles vaccination, EZ = standard titre Edmonston-Zagreb measles vaccine, SW = standard titre Schwarz measles vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Measles vaccine
Description: The children will be randomised to the following three arms:~Arm 1 - Very early two-dose: V (EZ) 4½ mo of age + V (EZ) 9 mo of age.~Arm 2 - 9 months one- or two-dose: V (SW) 9 mo of age + V (SW)/or nothing 18 mo of age.~Arm 3 - 9 months one- or two-dose: V (EZ) 9 mo of age + V (EZ)/or nothing 18 mo of age.~V = measles vaccination, EZ = standard titre Edmonston-Zagreb measles vaccine, SW = standard titre Schwarz measles vaccine
Study: NCT01306058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRC 105
Description: 15 mg/kg intravenous (IV) every 2 weeks
Study: NCT00168558

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Measles vaccine
Description: The children will be randomised to the following three arms:~Arm 1 - Very early two-dose: V (EZ) 4½ mo of age + V (EZ) 9 mo of age.~Arm 2 - 9 months one- or two-dose: V (SW) 9 mo of age + V (SW)/or nothing 18 mo of age.~Arm 3 - 9 months one- or two-dose: V (EZ) 9 mo of age + V (EZ)/or nothing 18 mo of age.~V = measles vaccination, EZ = standard titre Edmonston-Zagreb measles vaccine, SW = standard titre Schwarz measles vaccine
Study: NCT02626260

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: adhesive strip
Description: Adhesive strip with a standard adhesive base
Study: NCT01323062

Intervention type: DRUG
Group type: OTHER
Intervention: Bavituximab
Description: Administered 3 mg/kg weekly
Study: NCT01539525

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as Usual
Description: Subjects given a brochure listing relevant recovery resources in the local area.
Study: NCT02034266

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation
Description: 5 mL twice daily, administered under the tongue
Study: NCT01603251

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-lumefantrine combination
Description: Artemether-Lumefantrine (AL)combination; a placebo is given together with the first and fifth dose of AL
Study: NCT01306058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 400 mg twice a day (bid) continuously in a 28 days cycle
Study: NCT02004405

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: strengthening exercise
Description: The experimental group (STRE) will receive strengthening training in Station for lifting weight exercises (Flex Mega 8, Flex Fitness Equipment Brand) using the recommendations of the American College of Sports Medicine (ACMS, 2010), twice a week, during 45 minutes for 16 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: flexibility exercise
Description: The control group (FLEX) will receive stretching and flexibility exercise training according to the protocol of prescription and previously tested and described in appendix F (Valim et al., 2003), twice a week, during 45 minutes for 16 weeks.
Study: NCT01316692

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: TdT-mediated dUTP nick end labeling assay
Description: Correlative studies
Study: NCT01627639

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide
Description: Acetazolamide (1 g IV per day or 2 g IV per day if coprescription of loop diuretics) or Placebo (saline serum) when pure or mixed metabolic alkalosis being present until planned extubation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04013763

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: wheat containing skin care products
Description: stop or continue using wheat containing skin care products

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: wheat containing skin care products
Description: stop or continue using wheat containing skin care products
Study: NCT01316692

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mass spectrometry
Description: Correlative studies
Study: NCT00546858

Intervention type: OTHER
Intervention: Physical Examination
Description: Patients will be invited to be evaluated in the Urology Research office at a future date.
Study: NCT04575805

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered Combined Cognitive Bias Modification (iCBM-C)
Description: The iCBM-C is online CBM intervention which is the combination of iCBM-I and iCBM-A interventions for obsessive-compulsive symptoms delivered in eight sessions, twice per week for 4 weeks. The presentation order of the two intervention components will be counterbalanced to allow exploration of any order effects. Thereby, half of the participants in iCBM-C group will complete the iCBM-A task followed by iCBM-I, while the other half will complete the iCBM-I task followed by iCBM-A during each session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered Cognitive Bias Modification-Interpretation (iCBM-I)
Description: The iCBM-I is online CBM intervention for obsessive-compulsive symptoms comprised of delivery of OCD related scenarios taking place over eight sessions, twice per week for 4 weeks.
Study: NCT01603251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine combination + single dose Ivermectin
Description: Artemether-lumefantrine (AL) combination + Ivermectin (200ug/kg) given once together with the first dose of AL. A placebo is given together with the fifth dose of AL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine combination + repeated dose Ivermectin
Description: Artemether-lumefantrine (AL) combination + Ivermectin (200ug/kg) given together with the first and fifth dose of AL.
Study: NCT03393845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200mg IV, 21 day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant, 500mg IM, Loading dose: C1 D1 \& 15. Thereafter, Q4 wks
Study: NCT00920465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mifegyne and cytotec
Description: One day dosage versus two days dosage

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mifegyne and cytotec
Description: One day dosage versus two days dosage
Study: NCT03388983

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6-week prehabilitation
Description: Participants will be trained at 3 sessions/week for 6 weeks before the surgery to enhance the overall muscle strength, endurance and spinal stability. A physiotherapist/physical trainer in the participating hospital will supervise the preoperative training. The 45-minute exercise regime will include warm-up and cool-down exercises, and a cardiovascular training on a stationary bicycle, stabilization exercises with emphasis on co-contraction of abdominal and back muscles, and hip raise and hip abduction exercises. The number of repetitions and sets of each exercise will be determined based on individual's ability. Each exercise will be slightly modified based on individual progress. The exercise intensity and complexity will be increased over time.
Study: NCT00835094

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mometasone furoate
Description: MF-DPI 400 mcg once daily in the morning for 12 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mometasone furoate
Description: MF-DPI 400 mcg once daily in the evening for 12 weeks
Study: NCT02829346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peri-articular tranexamic acid
Description: 750 mg of peri-articular TXA, prior to deflating the tourniquet and wound closure

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous tranexamic acid
Description: 750 mg of IV TXA, prior to deflating the tourniquet and wound closure
Study: NCT01390701

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous electrical nerve stimulation
Description: 30 min of bi-daily low-frequency transcutaneous electrical nerve stimulation on the upper extremities. Duration: 28+-4 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: felodipin
Description: 2,5mg of felodipin once daily. Duration: 28+-4 days.
Study: NCT00976768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin, 5-fluorouracil
Description: Oxaliplatin 85 mg/㎡ IV, day 1 over 2 hours 5-FU 400 mg/㎡ IV bolus day 1 followed by 5-fluorouracil(FU) 2,400 mg/㎡ and leucovorin (LV) 100 mg/㎡ IV continuous over 46 hours (every 2 weeks)
Study: NCT02371733

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Upper extremity aerobic exercise training
Description: Training group will receive upper extremity aerobic exercise training using arm ergometer at 50-80% of maximal heart rate and breathing exercises.~Training will exercise with arm ergometer 3days/week, for 6 weeks with the assistance of a physiotherapist. Training workload will be undercontrol both using target heart rate and Modified Borg dyspnea scale. Training group will also perform breathing exercises 120 times/day, 7 days/week, for 6 weeks.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Alternative upper extremity exercises
Description: Control group will receive alternative upper extremity exercises and breathing exercises. Control group will perform alternative upper extremity exercises 3days/week, for 6 weeks and also breathing exercises 120 times/day, 7 days/week, for 6 weeks.~Control group will be followed-up by telephone once a week.
Study: NCT03743558

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: smartphone homemade video
Description: value of a video recording of the child sleep on smartphone made by the parents
Study: NCT00841295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parenteral L-carnitine supplementation
Description: Parenteral carnitine supplementation (9 ± 1 mg/kg/d), from day 4, until than enteral nutrition provides sufficient carnitine source.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Parenteral supplementation with sterile water
Description: Parenteral supplementation with an equivalent volume of sterile water
Study: NCT02629081

Intervention type: OTHER
Intervention: Controls & Cases
Description: All interventions are standard of care and both controls and cases will be treated the same. IEE results from controls and cases will be compared.
Study: NCT01400334

Intervention type: RADIATION
Intervention: Positron Emission Tomography
Description: Quantification of cardiac function using positron emission tomography and: a)11C-meta-hydroxyephedrine \[HED, 20 mCi (740 MBq)\] to quantify sympathetic nerve function, b) 13N-ammonia \[NH3, 20 mCi (740 MBq)\] for regional perfusion, and c) 18F-2-deoxyglucose \[FDG; 6.5 mCi (241 MBq)\] administered during a hyperinsulinemic-euglycemic clamp to assess viability.
Study: NCT00592358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paliperidone
Description: tablet, 3mgQAM - 6mgQAM, taken daily for 8 weeks
Study: NCT03843658

Intervention type: OTHER
Intervention: There is no intervention, but a diagnosis.
Description: Cohorts will be determined by the primary rheumatology diagnosis.

Intervention type: OTHER
Intervention: There is no intervention, but a diagnosis.
Description: Cohorts will be determined by the primary rheumatology diagnosis.

Intervention type: OTHER
Intervention: There is no intervention, but a diagnosis.
Description: Cohorts will be determined by the primary rheumatology diagnosis.

Intervention type: OTHER
Intervention: There is no intervention, but a diagnosis.
Description: Cohorts will be determined by the primary rheumatology diagnosis.

Intervention type: OTHER
Intervention: There is no intervention, but a diagnosis.
Description: Cohorts will be determined by the primary rheumatology diagnosis.
Study: NCT01243606

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single Diagnosis Treatment Protocol
Description: SDPs include: Managing Social Anxiety: A CBT Approach; Mastery of Anxiety and Panic-IV; Mastery of Anxiety and Worry-II; and Obsessive-Compulsive Disorder: A CBT Approach
Study: NCT02495935

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OkuStim®
Description: Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-OkuStim®
Description: Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany
Study: NCT01299532

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Macrolane VRF30
Description: Device: Macrolane VRF30 (stabilized hyaluronic acid of non-animal origin) Treatment: Initial injection of a maximum of 120 ml/breast. Re-injection of a maximum of 120 ml/breast in a subgroup of subjects.
Study: NCT02838706

Intervention type: PROCEDURE
Intervention: Surgery for hip fracture
Study: NCT01243606

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified Protocol (UP)
Description: The UP is designed to help patients learn how to confront and experience uncomfortable emotions and learn how to respond to their emotions in more adaptive ways. Individual treatment sessions will be conducted by experienced clinicians who will be trained in the administration of this protocol. A workbook will be provided to each patient as part of this manualized treatment. Treatment and session length of the UP will be matched to the SDPs for each principal diagnosis (see description above).
Study: NCT00653796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe + Atorvastatin
Description: oral tablets: ezetimibe 10 mg + atorvastatin 10 mg once daily for 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: oral tablets: atorvastatin 10 mg + ezetimibe placebo once daily for 6 weeks
Study: NCT00628511

Intervention type: DEVICE
Intervention: ARES (Apnea Risk Evaluation System)
Description: application of portable monitoring device with PSG
Study: NCT03572543

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tDCS
Description: Subjects will receive 20 minutes of multifocal transcranial direct current stimulation. The anode will be placed over the frontal pole (Fpz, 10-20 EEG) and will be surrounded by 5 return electrodes (cathodes). Current will be set at 1.5mA and will be ramped in/out at the begging and end of the 20-minutes of stimulation over the course of 30 seconds.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: Subjects will receive 20 minutes of multifocal transcranial direct current stimulation. The anode will be placed over the frontal pole (Fpz, 10-20 EEG) and will be surrounded by 5 return electrodes (cathodes). Current will be set at 1.5mA and will be ramped in/out at the begging and end of the 20-minutes of stimulation over the course of 30 seconds.
Study: NCT00854529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: sub-conjunctival injection of 1.25mg Bevacizumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: sub-conjunctival injection of 1.25mg Bevacizumab
Study: NCT00918528

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Internal urethrotomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Internal urethrotomy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin C - local injection
Study: NCT03888300

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: Chest Physiotherapy, physical exercises
Study: NCT03238248

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine Subcutaneous Injection or Intravenous Infusion
Description: 75 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pevonedistat Infusion
Description: 20 mg/m2

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy & Aspirate
Description: Removal of a small piece of bone and bone marrow by inserting a needle into hip bone.
Study: NCT03616587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9833
Description: Part A: AZD9833 monotherapy dose escalation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9833
Description: Part B: AZD9833 monotherapy expansion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9833 with palbociclib
Description: Part C: AZD9833 in combination with palbociclib dose escalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9833 with palbociclib
Description: Part D: AZD9833 in combination with palbociclib expansion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9833 with everolimus
Description: Part E: AZD9833 in combination with everolimus dose escalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9833 with everolimus
Description: Part F: AZD9833 in combination with everolimus dose expansion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9833 with abemaciclib
Description: Part G: AZD9833 in combination with abemaciclib (± anastrozole) dose escalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9833 with abemaciclib
Description: Part H: AZD9833 in combination with abemaciclib (± anastrozole) dose expansion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9833 with capivasertib
Description: Part I: AZD9833 in combination with capivasertib dose escalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9833 with capivasertib
Description: Part J: AZD9833 in combination with capivasertib dose expansion
Study: NCT00289718

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Twinrix™ adult
Description: Intramuscular administration
Study: NCT01810965

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: First evaluation phase : no intervention / Second evaluation phase: bloodletting of 7 ml/kg (with a maximum of 500ml)
Study: NCT01402895

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Transversus abdominus exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mobilizations
Description: The physiotherapist will perform mobilizations to the L-spine and SI joints with the participant in a specific position.
Study: NCT03265327

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral supplement containing omega-3 and omega-6
Description: An oral supplement containing omega-3 and omega-6

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Oral supplement containing coconut and olive oil
Description: An oral supplement containing coconut oil and olive oil
Study: NCT03447184

Intervention type: DRUG
Intervention: Androgen priming
Description: Androgen priming: with a low dose of recombinant hCG, aromatase inhibitor, and a depot GnRHa for 8 weeks Stimulation: a standard rFSH stimulation with either 300 IU rFSH or 300 IU (rFSH + rLH) Blood sampling: 6 blood samples to measure FSH, LH, E2, testosterone, and AMH Ultrasound examination: to count all antral follicles, 2-10 mm in each ovary Follicular fluid: to analyze E2, androstenedione, testosterone, progesterone, inhibin B.~Granulosa cells: to analyze gene expression in cumulus and mural granulosa cells of Luteinising hormone receptor (LHR), 3β-hydroxy-steroid-dehydrogenase (3ßHSD), inhibin-Ba (INHB-A) receptor, androgen and FSH receptor
Study: NCT01955980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Inhalation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: Nasal Spray
Study: NCT00880685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: 10-30mg, daily for 8 weeks
Study: NCT04300621

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTF 1
Description: Participants will receive (S)-ketamine administered sublingually through OTF 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTF 1
Description: Participants will receive (S)-ketamine administered sublingually through OTF 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTF 1
Description: Participants will receive (S)-ketamine administered sublingually through OTF 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTF 1
Description: Participants will receive (S)-ketamine administered sublingually through OTF 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTF 2
Description: Participants will receive (S)-ketamine administered sublingually through OTF 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTF 2
Description: Participants will receive (S)-ketamine administered sublingually through OTF 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTF 2
Description: Participants will receive (S)-ketamine administered sublingually through OTF 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTF 2
Description: Participants will receive (S)-ketamine administered sublingually through OTF 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTF 3
Description: Participants will receive (S)-ketamine administered sublingually through OTF 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTF 3
Description: Participants will receive (S)-ketamine administered sublingually through OTF 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTF 3
Description: Participants will receive (S)-ketamine administered sublingually through OTF 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTF 3
Description: Participants will receive (S)-ketamine administered sublingually through OTF 3.
Study: NCT02218398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol
Study: NCT01499043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX3397
Description: Capsules administered twice daily, continuous dosing. Subjects will take PLX3397 at 1000 mg/day.
Study: NCT03185741

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UMS Strategy
Description: Patients of providers randomized to the UMS arm will receive study-related educational tools at their primary care visit to support the understanding, regimen consolidation, and use of prescriptions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UMS Strategy
Description: Patients of providers randomized to the UMS arm will receive study-related educational tools at their primary care visit to support the understanding, regimen consolidation, and use of prescriptions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS Text Messaging
Description: Patients will receive daily text message reminders about when to take medicines based on UMS intervals.